Compare BBSI & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBSI | DRUG |
|---|---|---|
| Founded | 1965 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 799.2M | 744.9M |
| IPO Year | 1994 | 2020 |
| Metric | BBSI | DRUG |
|---|---|---|
| Price | $40.10 | $75.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $42.67 | ★ $129.25 |
| AVG Volume (30 Days) | 218.6K | ★ 257.8K |
| Earning Date | 05-06-2026 | 05-15-2026 |
| Dividend Yield | ★ 1.01% | N/A |
| EPS Growth | ★ 5.05 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $920,432,000.00 | N/A |
| Revenue This Year | $6.59 | N/A |
| Revenue Next Year | $6.05 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9.50 | N/A |
| 52 Week Low | $25.33 | $25.56 |
| 52 Week High | $49.65 | $123.75 |
| Indicator | BBSI | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 72.73 | 57.59 |
| Support Level | $33.19 | $72.18 |
| Resistance Level | $45.53 | $91.80 |
| Average True Range (ATR) | 1.28 | 5.48 |
| MACD | 0.21 | 1.30 |
| Stochastic Oscillator | 85.15 | 82.27 |
Barrett Business Services Inc is a provider of business management solutions for small and mid-sized companies through a platform that combines management consulting expertise with human resource tools to help business owners manage and operate their businesses more effectively. The company has two categories of services: Professional Employer Services (PEO) and Staffing. The majority of revenue is derived from the Professional Employer Services segment, which provides clients with human resource advisory services, HRIS access, retirement plans, a learning management system, and a web-based technology platform, myBBSI.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.